VEGFR2/CD309 anticorps (AA 949-953)

N° du produit ABIN362634

Détail du produit anti-VEGFR2/CD309 anticorps

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Épitope: AA 949-953

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp VEGFR2/CD309 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)

Specificité: The antibody detects endogenous level of total VEGFR2 protein.

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography usingepitope-specific immunogen.

Immunogène: Peptide sequence around AA 949-953 (K-D-Y-V-G) derived from Human VEGFR2. Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates.

Isotype: IgG

Information d'application

Indications d'application: Western blotting: 1:500-1:1000
Immunohistochemistry: 1:50-1:100
Immunofluorescence: 1:100-1:200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at -20 °C for long term preservation (recommended). Store at 4 °C for short term use.

Références pour anticorps anti-VEGFR2/CD309 (ABIN362634)

Zhao, Niu, Matsumoto, Tsuneyama, Tanaka, Miyata, Yokozawa: "Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain." dans: BMC complementary and alternative medicine, Vol. 12, pp. 188, (2013) (PubMed).

Zhao, Yokozawa, Tsuneyama, Tanaka, Miyata, Shibahara, Matsumoto et al.: "Chotosan (Diaoteng San)-induced improvement of cognitive deficits in senescence-accelerated mouse (SAMP8) involves the amelioration of angiogenic/neurotrophic factors and neuroplasticity systems in ..." dans: Chinese medicine, Vol. 6, pp. 33, (2011) (PubMed).

Détails sur VEGFR2/CD309

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Autre désignation: VEGFR2 (VEGFR2 Produits)

Synonymes: anticorps CD309, anticorps FLK1, anticorps VEGFR, anticorps VEGFR2, anticorps 6130401C07, anticorps Flk-1, anticorps Flk1, anticorps Krd-1, anticorps Ly73, anticorps VEGFR-2, anticorps sVEGFR-2, anticorps Vegfr-2, anticorps FLK-1, anticorps flk-1, anticorps vegfr-2, anticorps KDR, anticorps FLK/KDR, anticorps flk1, anticorps flk1b, anticorps kdrb, anticorps si:busm1-205d10.1, anticorps si:ch211-254j6.1, anticorps si:ch211-278f21.4, anticorps wu:fc31a09, anticorps fk52c05, anticorps flk, anticorps kdr, anticorps kdra, anticorps vegfr2, anticorps vegfr4, anticorps vegr2, anticorps wu:fk52c05, anticorps kinase insert domain receptor, anticorps kinase insert domain protein receptor, anticorps vascular endothelial growth factor receptor kdr-like, anticorps kinase insert domain receptor (a type III receptor tyrosine kinase), anticorps kinase insert domain receptor like, anticorps KDR, anticorps Kdr, anticorps LOC100136647, anticorps kdr, anticorps kdrl

Sujet: Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions

Poids moléculaire: 230 kDa

NCBI Accession: NP_002244

UniProt: P35968

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling